Aranesp Fails in RED-HF Trial
(MedPage Today) -- The RED-HF trial, testing darbepoetin alfa (Aranesp) in heart failure patients with anemia, failed to meet its primary endpoint, according to top-line results released by Amgen. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 17, 2013 Category: Cardiology Source Type: news

Darbepoetin alfa disappoints in RED-HF
Sponsors for the RED-HF trial say no new safety concerns arose with the drug, but treatment had no benefit over placebo in terms of reducing death from any cause or first hospital admission for worsening HF in patients with left ventricular systolic dysfunction and anemia. (Source: theHeart.org)
Source: theHeart.org - January 17, 2013 Category: Cardiology Source Type: news

Phase III trial of darbepoetin alfa (Aranesp) in heart failure fails to meet primary efficacy endpoint
Source: PharmaLive Area: News Amgen has announced that its phase III Aranesp® (darbepoetin alfa) RED-HF® (Reduction of Events With Darbepoetin Alfa in Heart Failure) trial has failed to meet its primary efficacy endpoint.   The trial was initiated in 2006, and recruited 2278 patients with symptomatic systolic heart failure and anaemia (haemoglobin 9.0 to 12.0 g/dL) who were randomised to receive either treatment with darbepoetin to achieve a target haemoglobin of at least 13.0 g/dL (not to exceed 14.5 g/dL), or placebo. The study primary endpoint was a reduction in the composite endpoint of time to death from a...
Source: NeLM - Cardiovascular Medicine - January 17, 2013 Category: Cardiology Source Type: news

Amgen Trial Fails To Show Benefit Of Anemia Drug In Heart Failure Patients
The bad news continues for Aranesp (darbepoetin alfa), Amgen's long-acting erythropoietin-stimulating agent. The drug is intended to stimulate red cell blood production in patients with anemia. Amgen today announced the top line results of a large phase 3 heart failure trial of the drug and said  the trial had failed to meet its primary endpoint. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 16, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
FORT WASHINGTON, Pa., December 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the use of erythropoietin-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa. ESAs are no longer recommended for the treatment of cancer-related anemia associated with solid tumors or hematologic malignancies other than myelodysplastic syndromes (MDS). ESA therapy is an option for patient... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 20, 2007 Category: Cancer & Oncology Source Type: news

NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
JENKINTOWN, Pa., March 5, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. A significant issue the panel addressed was the results of a trial by Amgen, Inc. studying the use of Aranesp (darbepoetin alfa)... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - March 5, 2007 Category: Cancer & Oncology Source Type: news